Background and Objectives: the on-going COVID-19 pandemic is responsible for over 5 million deaths worldwide. The SARS-COV2 virus is now well known to affect respiratory, cardiovascular and neurological systems. Troponin I, traditionally used as a cardiac biomarker usually for the diagnosis of acute coronary syndrome (ACS). Troponin I levels were found to be raised in COVID patients requiring admission to the ICU. This study is aimed to evaluate the relationship between Troponin I and mortality in such patients and whether Troponin I levels can be used as a prognostic tool to determine severity in COVID patients. Materials and Methods: This study included patients diagnosed with COVID-19 via RTPCR from nasopharyngeal and pharyngeal samples, who were admitted to the ICU between May 2021 and August 2021. The Troponin I levels were measured for each patient at the time of admission and the patients were stratified into two groups (elevated vs. normal). Data was retrospectively reviewed and analysed. Results: The study included 257 COVID patients requiring admission to the ICU. Patients with elevated Troponin I levels were found to be older (77±13 vs. 58±16 years, p<0.0001). They were also more likely to be suffering from diabetes (p=0.0019), hypertension (p<0.0001), coronary artery disease (p<0.0001) and heart failure (p=0.0011). Patients with raised Troponin I levels at admission were more likely to have higher all-cause mortality (52% vs. 10%, p<0.0001). Conclusion: Elevation of Troponin I is commonly seen in patients with severe SARS-COV2 infection and is significantly associated with increased mortality.